GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » ROIC %

SCPX (Scorpius Holdings) ROIC % : -82.51% (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Scorpius Holdings's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -82.51%.

As of today (2024-12-15), Scorpius Holdings's WACC % is 6.44%. Scorpius Holdings's ROIC % is -59.28% (calculated using TTM income statement data). Scorpius Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Scorpius Holdings ROIC % Historical Data

The historical data trend for Scorpius Holdings's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scorpius Holdings ROIC % Chart

Scorpius Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -136.36 -177.25 -177.04 -87.95 -70.35

Scorpius Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.55 -44.23 -49.18 -68.91 -82.51

Competitive Comparison of Scorpius Holdings's ROIC %

For the Biotechnology subindustry, Scorpius Holdings's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scorpius Holdings's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's ROIC % distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's ROIC % falls into.



Scorpius Holdings ROIC % Calculation

Scorpius Holdings's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-42.032 * ( 1 - 1.35% )/( (67.167 + 50.711)/ 2 )
=-41.464568/58.939
=-70.35 %

where

Scorpius Holdings's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:

ROIC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-39.42 * ( 1 - 0% )/( (48.852 + 46.702)/ 2 )
=-39.42/47.777
=-82.51 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scorpius Holdings  (AMEX:SCPX) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Scorpius Holdings's WACC % is 6.44%. Scorpius Holdings's ROIC % is -59.28% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Scorpius Holdings ROIC % Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scorpius Holdings Business Description

Traded in Other Exchanges
N/A
Address
627 Davis Drive, Suite 400, Morrisville, NC, USA, 27560
Scorpius Holdings Inc is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities.
Executives
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf director, officer: Chief Executive Officer 3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii director C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander officer: CFO/Corp Secy 801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan director
Robert James Jakobs officer: VP Finance/Controller/Secty PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins officer: Chief Scientific Officer 15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar officer: VP of Finance and Controller C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov director 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech officer: Chief Financial Officer C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber officer: Vice President of Research 100 EUROPA DRIVE, CHAPEL HILL NC 27517